论文部分内容阅读
目的:探讨依达拉奉、脑复康治疗脑出血的临床疗效与安全性。方法:将80例脑出血患者随机分成2组:依达拉奉脑复康组(治疗组)和常规治疗组(对照组),每组40例。观察治疗组和对照组在治疗2周、4周后,以对比治疗组和对照组治疗有效率及不良反应。结果:治疗组神经功能有效改善,总有效率95%,对照组神经功能有效改善,总有效率75%。结论:依达拉奉脑复康联合用药治疗脑出血疗效显著。
Objective: To investigate the clinical efficacy and safety of edaravone and naofukang in the treatment of cerebral hemorrhage. Methods: Eighty patients with cerebral hemorrhage were randomly divided into two groups: edaravone and lumbar rehabilitation group (treatment group) and conventional treatment group (control group), 40 cases in each group. Observation treatment group and control group in the treatment of 2 weeks, 4 weeks later, to compare the treatment group and control group, the treatment efficiency and adverse reactions. Results: The neurological function of the treatment group was effectively improved, the total effective rate was 95%. The neurological function of the control group was effectively improved with a total effective rate of 75%. Conclusion: Edaravone Naofukang combined with drugs for the treatment of cerebral hemorrhage significant effect.